Infarmed Reads SNS Medicine Spend at a Record €4.417 Billion in 2025 — Hospital Drugs Cross €2.5 Billion for the First Time as Oncology Adds €864.5 Million at +16% and Ambulatory Comparticipação Lifts to €1.894 Billion at +12.4%

The Serviço Nacional de Saúde spent a record €4,417 million on medicines in 2025, according to the Infarmed monitor whose summary tables hit the wires on Tuesday 19 May 2026. The headline is +60% above the 2020 pandemic baseline of €2,759 million and the first time the combined hospital + ambulatory comparticipação line has crossed €4.4 billion. Lusa carries the data; RTP, Jornal de Negócios and Público run it as their lead Tuesday-morning health beat.

The two engines, broken out

Hospital medicines lifted to €2,523 million in 2025 — a +11.2% step-up and the first print above €2.5 billion in the series. Ambulatory comparticipação — the state's contribution to retail-pharmacy prescriptions — closed at €1,894 million, up 12.4% on 2024. Both engines posted double-digit growth for the fourth year running; the 2020-2025 cumulative for the hospital book is closer to +90%.

The hospital number carries a heavy concentration: oncology drugs alone landed at €864.5 million in 2025, up 16% year-on-year, and now represent roughly one-third of all hospital-medicine spend. Orphan drugs — the regulatory bucket for rare-disease therapies — added €465 million at +34.1%, the fastest-growing line in the entire 2025 file. HIV-treatment spend came in at €238.2 million; vaccines, a smaller bucket, jumped 69.8% to €85.5 million as the post-pandemic vaccination calendar normalised inside the SNS budget.

Q1 2026 already running ahead

The first-quarter 2026 hospital read is €693.4 million, +7.6% on Q1 2025 — slightly below the 2024-2025 cadence but still firmly in double-digit annualised territory once the back-end-of-year clinical-trial closures and innovative-therapy authorisations are factored in. The ambulatory Q1 2026 read for families lands at €243.1 million, +1.3% on Q1 2025, a sharp deceleration from the 2025 full-year +4.9% read that suggests the recent generics-share push is starting to bite at the household level.

What families paid out of pocket

Portuguese households spent €966 million on medicines in 2025, up 4.9% from €920.7 million in 2024. The Infarmed breakdown gives the average per-package out-of-pocket cost at €4.67 in Q1 2026 (-1.2% year-on-year), with the average SNS reimbursement at €9.60 (+6.9%) — the wedge between what the state pays and what the patient pays is widening, in the patient's favour, where comparticipação rules are being recalibrated upwards. Generic medicines accounted for 50.9% of all outpatient prescriptions in 2025, rising to 63.7% in therapeutic classes with available alternatives.

The drug-class mosaic

Antidislipidémicos — the cholesterol and triglyceride class led by atorvastatin — remain the single most-dispensed therapeutic line at 21.3 million packages in 2025, +9.7%. The top four active substances by package volume read: atorvastatina (8.5 million packages), paracetamol (4.8M), bisoprolol (3.9M) and metformina (3.4M). On the ambulatory comparticipação spend line, antidiabéticos lift to €478.9 million at +14.7% — a number that will be read alongside the parallel Government decision window on GLP-1 emagrecimento comparticipação that the Health Ministry committed to close next week.

Read across

The Infarmed monitor is the cleanest single-source read on SNS pharma run-rate; it lands ahead of the OPSS Primavera report due later in May and ahead of the OE2026 mid-year execution review. Three implications for the policy file already in motion:

• OE2026 envelope risk. If Q1 2026 hospitals run +7.6% and the 2025 full-year was +11.2%, the OE2026 medicines line — built on a conservative single-digit-growth assumption — has very little slack left for an oncology or orphan-drug authorisation tide in H2.
• EY-Parthenon read coherent. The 18 May private-health-coverage saving of €1.945 billion in 2023 is built on private insurers absorbing a portion of the same therapy mix that is driving the +16% oncology line; both readings point at innovative oncology and rare-disease therapies as the structural cost driver across both health systems.
• Drug-access pipeline pressure. The 18 May Lusa read on the 650-day average between EU authorisation and SNS funding decision now reads as a one-sided fiscal lever: the longer the delay, the more the pent-up demand pushes into the comparticipação book once the funding decision lands.

The full Infarmed series — including the therapeutic-class-by-therapeutic-class breakdown for 2025 — will land in the formal Monitorização Mensal report next week. The Q1 2026 update will be the first read of how the 2026 envelope is tracking against the OE assumption.